Prevention of hyponatraemia and cerebral oedema by the vasopressin antagonist d/CH2/5Tyr/Et/VAVP in rats treated with pitressin tannate.
A rat model of the Schwartz-Bartter syndrome was created by the administration of a high dose of a long-acting vasopressin preparation (pitressin tannate ) together with a forced water intake. The treatment led to water retention, hypernatriuria , marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta- cyclopentamethylene -propionic acid),2-0- ethyltyrosine ,4-valine]arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz-Bartter syndrome.
D000818:Animals; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000494:pharmacology; D001834:Body Water / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D001929:Brain Edema / Q000517:prevention & control*; D004231:Diuresis / Q000187:drug effects; D007010:Hyponatremia / Q000517:prevention & control*; D007177:Inappropriate ADH Syndrome / Q000517:prevention & control*; D008297:Male; D009994:Osmolar Concentration; D051381:Rats; D011919:Rats, Inbred Strains; D014554:Urination / Q000187:drug effects; D014667:Vasopressins / Q000494:pharmacology*
C016671:pitressin tannate; D014667:Vasopressins; D001127:Arginine Vasopressin; C015981:argipressin,beta-mercapto-beta,beta-cyclopentamethylenepropionic acid(1)-Val(4)-